USPTO Patent Application: Polynucleotides Targeting NR4A3
Summary
The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.
What changed
The United States Patent and Trademark Office (USPTO) has published patent application US20260083846A1, filed by Lyell Immunopharma, Inc. The application, with a filing date of May 19, 2023, details polynucleotides, specifically gRNAs, designed to reduce NR4A3 gene or protein levels in cells. These polynucleotides are intended for therapeutic use in treating various diseases and disorders, including cancer.
This publication represents a new patent application and does not impose immediate compliance obligations. However, it signifies ongoing innovation in the therapeutic use of gene-targeting technologies. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in gene therapy or oncology, should note this development for competitive intelligence and potential licensing or collaboration opportunities. The patent is scheduled for publication on March 26, 2026.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
POLYNUCLEOTIDES TARGETING NR4A3 AND USES THEREOF
Application US20260083846A1 Kind: A1 Mar 26, 2026
Assignee
Lyell Immunopharma, Inc.
Inventors
Viola LAM, Rachel Christina LYNN
Abstract
The present disclosure provides polynucleotides that are capable of reducing the level of a NR4A3 gene and/or NR4A3 protein in a cell (e.g., immune cell). In some aspects, the polynucleotides comprises a gRNA that specifically targets a region within the NR4A3 gene. The present disclosure also provides the use of such polynucleotides to treat various diseases or disorders.
CPC Classifications
A61K 40/31 A61K 35/14 A61K 40/32 A61K 40/42 A61K 45/06 A61P 35/00 C07K 14/7051 C07K 16/00 C12N 5/0634 C12N 5/10 C12N 9/226 C12N 15/113 C12N 2310/20 C12N 2510/00
Filing Date
2023-05-19
Application No.
18867057
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.